Pyxis Oncology (PYXS)
Develops MICVO, an investigational ADC for difficult-to-treat solid tumors.
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of patients treated at or below a dose cap Updated data from the MICVO Phase 1/2 combination study with pembrolizumab in 1L R/M HNSCC on track to be reported in the fourth quarter of 2026 Completed private placement financing for up to $114 million, providing approximately $50 million in upfront gross proceeds to support additional patient follow-up Upfront proceeds from the private placement, together with existing cash, extended the Company's cash runway into the second quarter of 2027 BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended June 30, 2026, and highlighted continued advancement of the micvotabart pelidotin (MICVO) clinical development programs. “The second quarter was marked by continued execution across the MICVO program and a financing that strengthened our balance sheet and extended our cash runway into the second quarter of 2027,” said Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology.
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
GenSight Biologics (OTCMKTS:GSGTF - Get Free Report) and Pyxis Oncology (NASDAQ: PYXS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership. Insider and Institutional Ownership 39.1% of Pyxis Oncology
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a dose cap Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in the first quarter of 2026 Updated data from MICVO Phase 1/2 dose escalation study in combination with pembrolizumab in 1L R/M HNSCC on track for the second half of 2026 Presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026 that support the clinical development of MICVO as both a monotherapy and in combination with pembrolizumab for the treatment of R/M HNSCC Announced the appointment of Nelson Azoulay as Chief Business Officer Expected cash runway into the fourth quarter of 2026 BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the quarter ended March 31, 2026, and highlighted continued advancement of the micvotabart pelidotin (MICVO) clinical development program. “Our team's exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm for MICVO's potential to positively impact the lives of patients with cancer, has positioned us to deliver key milestones for the MICVO program this year,” said Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences:
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer.
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026
Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday
Pyxis Oncology (NASDAQ: PYXS - Get Free Report) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Pyxis Oncology to announce earnings of ($0.35) per share for the quarter. Parties may visit the the company's upcoming Q4 2025 earning results page for the latest details on the
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals.
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update
Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Currently, 4.1% of the company's stock are short sold. Based on an
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Pyxis Oncology, Inc. (NASDAQ: PYXS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company.
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The update includes preliminary data from both the Phase 1 monotherapy study in 2L+ R/M HNSCC and the Phase 1/2 study evaluating MICVO in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, pembrolizumab, in 1L/2L+ R/M HNSCC.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will participate in the following upcoming investor conferences in November 2025:
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 - Clinical update to focus on preliminary data from Phase 1 monotherapy dose expansion study of MICVO in 2L/3L R/M HNSCC patients, including from both post platinum & PD-1 and post EGFR & PD-1 arms, and preliminary data from Phase 1/2 combination dose escalation study of MICVO and KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC patients - Presented translational data at ESMO 2025 and AACR-NCI-EORTC providing meaningful insights into MICVO's first-in-concept non-cellular targeting antibody drug conjugate (ADC) mechanism of action - Expected cash runway through data milestones and into the second half of 2026 BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today provided a business update, and reported financial results for the quarter ended September 30, 2025. “In the dynamic landscape of emerging clinical-stage therapies for patients with recurrent and metastatic head and neck squamous cell carcinoma, a significant unmet medical need remains despite the potential improvements in treatment options,” said Lara S.
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MICVO's effects on tumor microenvironment remodeling and immune activation Translational data to be presented in two posters at ESMO 2025 and six posters at AACR-NCI-EORTC BOSTON, Oct.